Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Osimertinib”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Study completedNCT03463525
What this trial is testing

Open-label PET Study With [11C]Osimertinib in Patients With EGFRm NSCLC and Brain Metastases

Who this might be right for
Non-small Cell Lung Cancer
AstraZeneca 4
Testing effectiveness (Phase 2)Active Not RecruitingNCT04743505
What this trial is testing

Safety and Efficacy of Combining APL-101 With Frontline Osimertinib in Patients With EGFR-mutated Metastatic Non-small Cell Lung Cancer (NSCLC)

Who this might be right for
Metastatic Non Small Cell Lung Cancer
Washington University School of Medicine 27
Testing effectiveness (Phase 2)Looking for participantsNCT04410796
What this trial is testing

Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung Cancers

Who this might be right for
Metastatic Non-small Cell Lung Cancer
Memorial Sloan Kettering Cancer Center 571
Testing effectiveness (Phase 2)Looking for participantsNCT05281406
What this trial is testing

Additional Chemotherapy for EGFRm Patients with the Continued Presence of Plasma CtDNA EGFRm At Week 3 After Start of Osimertinib 1st-line Treatment (PACE-LUNG)

Who this might be right for
NSCLC Stage IIIBNSCLC Stage IV
Goethe University 50
Testing effectiveness (Phase 2)Active Not RecruitingNCT05880706
What this trial is testing

BL-B01D1 and BL-B01D1 in Combination With Osimertinib Mesylate Tablets in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer

Who this might be right for
Non-small Cell Lung Cancer
Sichuan Baili Pharmaceutical Co., Ltd. 198
Large-scale testing (Phase 3)Not Yet RecruitingNCT06380348
What this trial is testing

JMT101 in Combination With Osimertinib, Versus Cisplatin-pemetrexed in Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Exon 20ins Mutations

Who this might be right for
Local Advanced or Metastatic NSCLC
Shanghai JMT-Bio Inc. 398
Testing effectiveness (Phase 2)Active Not RecruitingNCT03122717
What this trial is testing

Osimertinib and Gefitinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer

Who this might be right for
Non-Small Cell Lung Cancer
Dana-Farber Cancer Institute 48
Large-scale testing (Phase 3)Study completedNCT02296125
What this trial is testing

AZD9291 Versus Gefitinib or Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer

Who this might be right for
Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer
AstraZeneca 674
Not applicableNo Longer AvailableNCT02451852
What this trial is testing

AZD9291 US Expanded Access Program

Who this might be right for
EGFR T790M Mutation Positive NSCLC
AstraZeneca
Testing effectiveness (Phase 2)UnknownNCT06018688
What this trial is testing

Osimertinib Combined With Aspirin Neoadjuvant Therapy for Resectable EGFR Mutated NSCLC Patients.

Who this might be right for
Non Small Cell Lung CancerEGFR Gene Mutation
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University 44
Large-scale testing (Phase 3)Looking for participantsNCT06417814
What this trial is testing

Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Who this might be right for
Metastatic Non-small Cell Lung Cancer
AstraZeneca 744
Testing effectiveness (Phase 2)Looking for participantsNCT06383728
What this trial is testing

Neoadjuvant Targeted Therapy in Patients With Resectable EGFR-mutated Lung Squamous Cell Carcinoma

Who this might be right for
Lung CancerCarcinoma, Squamous Cell
The First Affiliated Hospital of Guangzhou Medical University 51
Testing effectiveness (Phase 2)UnknownNCT04882345
What this trial is testing

Almonertinib Treats Advanced NSCLC Patients With EGFR Mutations Who Are Safety Intolerant After Osimertinib Treatment

Who this might be right for
Lung CancerEGFR Gene Mutation
Shanghai Chest Hospital 40
Large-scale testing (Phase 3)Active Not RecruitingNCT03521154
What this trial is testing

A Global Study to Assess the Effects of Osimertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer (LAURA)

Who this might be right for
Non Small Cell Lung Cancer (Stage III)
AstraZeneca 216
Very early researchStudy completedNCT03755102
What this trial is testing

A Pilot Study of Dacomitinib With or Without Osimertinib for Patients With Metastatic EGFR Mutant Lung Cancers With Disease Progression on Osimertinib.

Who this might be right for
EGFR Gene MutationLung CancerLung Cancer Metastatic
Memorial Sloan Kettering Cancer Center 17
Testing effectiveness (Phase 2)Study completedNCT03497767
What this trial is testing

A Randomised Phase II Trial of Osimertinib With or Without SRS for EGFR Mutated NSCLC With Brain Metastases

Who this might be right for
Metastatic Non Small Cell Lung Cancer
Trans Tasman Radiation Oncology Group 40
Testing effectiveness (Phase 2)Active Not RecruitingNCT05773092
What this trial is testing

Osimertinib and S-1 in Treatment Resistant EGFR Mutant NSCLC

Who this might be right for
NSCLC
National Cancer Centre, Singapore 30
Early research (Phase 1)Active Not RecruitingNCT05364073
What this trial is testing

Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Including Uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Mutations

Who this might be right for
Non-Small Cell Lung Cancer (NSCLC)Metastatic Non-Small Cell Lung CancerAdvanced Non-Small Cell Lung Cancer+3 more
ArriVent BioPharma, Inc. 160
Large-scale testing (Phase 3)Active Not RecruitingNCT04487080
What this trial is testing

Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Janssen Research & Development, LLC 1,074
Large-scale testing (Phase 3)Looking for participantsNCT07640789
What this trial is testing

A Study Comparing BL-B01D1 in Combination With Osimertinib Versus Osimertinib Alone in Patients With Locally Advanced, Unresectable EGFR-mutated Non-small Cell Lung Cancer(Stage III) Whose Disease Has Not Progressed Following Definitive Platinum-based Chemoradiation Therapy(PANKU-Lung08)

Who this might be right for
Non-small Cell Lung Cancer Stage III
Sichuan Baili Pharmaceutical Co., Ltd. 418
Next Page